NCT07250672 Patient-Specific 3D Action Observation Training in Parkinson's Disease
| NCT ID | NCT07250672 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abant Izzet Baysal University |
| Condition | Parkinson Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-12-15 |
| Primary Completion | 2027-07-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2025-12-15 with a primary completion date of 2027-07-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Although studies exist demonstrating the effects of single-session action observation training on bradykinesia in patients with Parkinson's disease, research investigating the long-term application of such training remains limited. Furthermore, the broader literature indicates that action observation training has typically been conducted in simulated environments or by using recordings obtained from healthy individuals. The aim of the present study is to examine the effects of action observation training, delivered in a fully immersive virtual reality environment using each patient's own 3D motion recordings, on bradykinesia and other disease-related parameters.
Eligibility Criteria
Inclusion Criteria: * Voluntary agreement to participate in the study * Clinical diagnosis of Parkinson's disease confirmed by a neurologist * Ongoing treatment with antiparkinsonian medication * Hoehn and Yahr (H-Y) stage ≤ 3 * Ability to walk independently Exclusion Criteria: * Presence of additional neurological disorders other than Parkinson's disease * Change in medication dosage within the past month * Score of ≥ 10 on the Simulator Sickness Questionnaire * Presence of amblyopia, strabismus, or pathologies impairing focus, depth perception, or normal 3D vision * Failure on the butterfly test of the Titmus stereotest (greater than 3,552 seconds of arc)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07250672 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 85 Years, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07250672 currently recruiting?
Yes, NCT07250672 is actively recruiting participants. Contact the research team at enestayyipbenli@gmail.com for enrollment information.
Where is the NCT07250672 trial being conducted?
This trial is being conducted at Bolu, Turkey (Türkiye).
Who is sponsoring the NCT07250672 clinical trial?
NCT07250672 is sponsored by Abant Izzet Baysal University. The trial plans to enroll 24 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.